Patel Mira A, Pardoll Drew M
Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
J Neurooncol. 2015 Jul;123(3):323-30. doi: 10.1007/s11060-015-1810-5. Epub 2015 Jun 13.
Immunotherapy is coming to the fore as a viable anti-cancer treatment modality, even in poorly immunogenic cancers such as glioblastoma (GBM). Accumulating evidence suggests that the central nervous system may not be impervious to tumor-specific immune cells and could be an adequate substrate for immunologic anti-cancer therapies. Recent advances in antigen-specific cancer vaccines and checkpoint blockade in GBM provide promise for future immunotherapy in glioma. As anti-GBM immunotherapeutics enter clinical trials, it is important to understand the interactions, if any, between immune-based treatment modalities and the current standard of care for GBM involving chemoradiation and steroid therapy. Current data suggests that chemoradiation may not preclude the success of immunotherapeutics, as their effects may be synergistic. The future of therapy for GBM lies in the power of combination modalities, involving immunotherapy and the current standard of care.
免疫疗法正作为一种可行的抗癌治疗方式崭露头角，即便在免疫原性较差的癌症如胶质母细胞瘤（GBM）中也是如此。越来越多的证据表明，中枢神经系统可能并非对肿瘤特异性免疫细胞毫无反应，并且可能是免疫抗癌疗法的合适作用底物。GBM中抗原特异性癌症疫苗和检查点阻断的最新进展为未来胶质瘤免疫疗法带来了希望。随着抗GBM免疫疗法进入临床试验，了解基于免疫的治疗方式与GBM当前的标准治疗（包括放化疗和类固醇治疗）之间的相互作用（如果存在的话）非常重要。目前的数据表明，放化疗可能并不妨碍免疫疗法取得成功，因为它们的效果可能具有协同作用。GBM治疗的未来在于联合治疗方式的力量，包括免疫疗法和当前的标准治疗。
